Clinical Trial Search

Primary: Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas. — 100; 102; 12 Participants

Primary: Mechanical Ventilation or Death — 9.9; 10.0; 10.6; 12.5 percentage of patients with event — p=0.64

Primary: Hemoglobin A1c at Baseline and Week 26 Endpoint With Last Observation Carried Forward (LOCF) Following Rivoglitazone or Pioglitazone Compared to Placebo as Monotherapy…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), TEAEs by Severity, and Serious Adverse Events (SAEs) (All Causality and Treatment-Related) — 5; 2…

Primary: Number of CBT Sessions Delivered by School Professionals to Students After 18 Months — 121.1; 111.4 number of CBT sessions — p=0.63

Primary: Potential of Abametapir Lotion to Cause Irritation After Repeated Topical Application to the Healthy Skin of Humans. — 1.10; 0.70; 1.10; 49.15 score on a scale

Primary: Immune-Related Overall Response Rate (irORR) — 0 percentage of participants

Primary: Change in Total Score for Concerns About Recurrence Scale [Adapted for Acute Coronary Syndrome] — -5.40; -2.86 change in score on a scale — p=0.698

Primary: Plasma Follistatin

Primary: Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit — 302.9; 286.6 score on a scale…

Primary: Mean Arterial Blood Pressure — 94.42; 93.41; 91.54; 90.21 mmHg

Primary: Participants With a Response — 23 Participants

Primary: Number of Participants Testing Positive or Negative for SARS-CoV-2 Virus From Swab and Saliva Samples - Processed in Mexico — 85; 13; 66; 89 Participants

Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants

Primary: Number of Employees Who Scheduled Vaccination Appointments After 3 Days — 101; 207; 220 Participants — p=<.001